share_log

Ikena Oncology Analyst Ratings

Benzinga ·  Sep 22, 2023 16:23
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/22/2023 164.42% Wedbush → $11 Initiates Coverage On → Outperform
08/10/2023 332.69% HC Wainwright & Co. → $18 Reiterates Buy → Buy
08/07/2023 332.69% HC Wainwright & Co. → $18 Reiterates Buy → Buy
05/24/2023 332.69% HC Wainwright & Co. → $18 Reiterates Buy → Buy
05/16/2023 212.5% Credit Suisse → $13 Reiterates Outperform → Outperform
05/04/2023 332.69% HC Wainwright & Co. → $18 Assumes → Buy
03/17/2023 428.85% HC Wainwright & Co. → $22 Reiterates → Buy
03/15/2023 212.5% Credit Suisse $16 → $13 Maintains Outperform
11/29/2022 284.62% Credit Suisse $18 → $16 Maintains Outperform
11/29/2022 428.85% HC Wainwright & Co. $26 → $22 Maintains Buy
11/08/2022 332.69% Credit Suisse $20 → $18 Maintains Outperform
05/13/2022 380.77% Credit Suisse $24 → $20 Maintains Outperform
04/13/2022 525% HC Wainwright & Co. $25 → $26 Maintains Buy
12/23/2021 500.96% HC Wainwright & Co. → $25 Initiates Coverage On → Buy
08/13/2021 549.04% Credit Suisse $30 → $27 Maintains Outperform
04/20/2021 Jefferies Initiates Coverage On → Buy
04/20/2021 William Blair Initiates Coverage On → Outperform
04/20/2021 621.15% Credit Suisse → $30 Initiates Coverage On → Outperform

What is the target price for Ikena Oncology (IKNA)?

The latest price target for Ikena Oncology (NASDAQ: IKNA) was reported by Wedbush on September 22, 2023. The analyst firm set a price target for $11.00 expecting IKNA to rise to within 12 months (a possible 164.42% upside). 11 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Ikena Oncology (IKNA)?

The latest analyst rating for Ikena Oncology (NASDAQ: IKNA) was provided by Wedbush, and Ikena Oncology initiated their outperform rating.

When is the next analyst rating going to be posted or updated for Ikena Oncology (IKNA)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ikena Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ikena Oncology was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.

Is the Analyst Rating Ikena Oncology (IKNA) correct?

While ratings are subjective and will change, the latest Ikena Oncology (IKNA) rating was a initiated with a price target of $0.00 to $11.00. The current price Ikena Oncology (IKNA) is trading at is $4.16, which is within the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment